Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 20:20, 17 December 2023

459 bytes added ,  20:20, 17 December 2023
no edit summary
Line 2: Line 2:  
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
 
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content
 
|-
 
|-
−
!Disease (5th Edition)!!Page Type!!Author (5th edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review!!Notes
+
!Disease (5th Edition)!!Page Type!!Author (5th Edition)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review!!Notes (5th Edition)
 +
!Notes (4th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Disease Name (4th Edition)
 
!Correlated Prior Author (4th Edition)
 
!Correlated Prior Author (4th Edition)
Line 11: Line 12:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 22: Line 24:  
|-
 
|-
 
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
 
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
 +
|
 
|NEW
 
|NEW
 
|NEW
 
|NEW
 
|-
 
|-
 
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
 
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
 +
|
 
|NEW
 
|NEW
 
|NEW
 
|NEW
 
|-
 
|-
 
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
 
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
 +
|
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|-
 
|-
 
|Chronic neutrophilic leukaemia||Disease|| || || || || ||FQR|| ||
 
|Chronic neutrophilic leukaemia||Disease|| || || || || ||FQR|| ||
 +
|
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Chronic Neutrophilic Leukemia (CNL)
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 
|-
 
|-
 
|Chronic eosinophilic leukaemia||Disease|| || || || || ||FQR|| ||
 
|Chronic eosinophilic leukaemia||Disease|| || || || || ||FQR|| ||
 +
|
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
 
|Chelsea D. Kramish; Daynna J.Wolff
 
|Chelsea D. Kramish; Daynna J.Wolff
 
|-
 
|-
 
|Polycythaemia vera||Disease|| || || || || ||FQR|| ||
 
|Polycythaemia vera||Disease|| || || || || ||FQR|| ||
 +
|
 
|Polycythemia Vera (PV)
 
|Polycythemia Vera (PV)
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 
|-
 
|-
 
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
 
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
 +
|
 
|Essential Thrombocythemia (ET)
 
|Essential Thrombocythemia (ET)
 
|
 
|
 
|-
 
|-
 
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
 
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
 
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
 
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
 
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
 
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
 
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
 
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
 
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
 
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
 +
|
 
|
 
|
 
|
 
|
Line 157: Line 191:  
|
 
|
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
 +
|
 
|
 
|
 
|
 
|
Line 170: Line 205:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 183: Line 219:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 196: Line 233:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 209: Line 247:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 222: Line 261:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 235: Line 275:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 248: Line 289:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 261: Line 303:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 274: Line 317:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 287: Line 331:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 300: Line 345:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 313: Line 359:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 326: Line 373:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 339: Line 387:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 352: Line 401:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 365: Line 415:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 378: Line 429:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 391: Line 443:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 404: Line 457:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 417: Line 471:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 430: Line 485:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 443: Line 499:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 456: Line 513:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 469: Line 527:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 482: Line 541:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 495: Line 555:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 508: Line 569:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 521: Line 583:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 534: Line 597:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 547: Line 611:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 560: Line 625:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 573: Line 639:  
|
 
|
 
|JH_MS
 
|JH_MS
 +
|
 
|
 
|
 
|
 
|
Line 583: Line 650:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 601: Line 669:  
|
 
|
 
|Greg Corboy (GC)
 
|Greg Corboy (GC)
 +
|
 
|
 
|
 
|
 
|
Line 614: Line 683:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 627: Line 697:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 640: Line 711:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 653: Line 725:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 666: Line 739:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 679: Line 753:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 692: Line 767:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 705: Line 781:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 718: Line 795:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 731: Line 809:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 741: Line 820:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 759: Line 839:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 772: Line 853:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 785: Line 867:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 798: Line 881:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 811: Line 895:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 824: Line 909:  
|
 
|
 
|Holli Drendel (HD)
 
|Holli Drendel (HD)
 +
|
 
|
 
|
 
|
 
|
Line 837: Line 923:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 850: Line 937:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 863: Line 951:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 876: Line 965:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 889: Line 979:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 902: Line 993:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 915: Line 1,007:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 928: Line 1,021:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 941: Line 1,035:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 954: Line 1,049:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 967: Line 1,063:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 980: Line 1,077:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 993: Line 1,091:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,000: Line 1,099:  
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
 
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,027: Line 1,131:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,040: Line 1,145:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,053: Line 1,159:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,066: Line 1,173:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,079: Line 1,187:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,092: Line 1,201:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,105: Line 1,215:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,118: Line 1,229:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,131: Line 1,243:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,144: Line 1,257:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,157: Line 1,271:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,170: Line 1,285:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,183: Line 1,299:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,196: Line 1,313:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,209: Line 1,327:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,215: Line 1,334:  
|-
 
|-
 
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
 
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
 
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
 
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
 
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
 
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
 
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
 
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
 
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
 
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
 
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
 
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
 
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
 
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
 
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
 
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
 
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
 
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
 
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
 
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,338: Line 1,486:  
|
 
|
 
|SG
 
|SG
 +
|
 
|
 
|
 
|
 
|
Line 1,344: Line 1,493:  
|-
 
|-
 
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,353: Line 1,504:  
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,358: Line 1,510:  
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,363: Line 1,516:  
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,368: Line 1,522:  
|Mu heavy chain disease||Disease|| || || || || ||SG
 
|Mu heavy chain disease||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,373: Line 1,528:  
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,378: Line 1,534:  
|Alpha heavy chain disease||Disease|| || || || || ||SG
 
|Alpha heavy chain disease||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,383: Line 1,540:  
|Plasmacytoma||Disease|| || || || || ||SG
 
|Plasmacytoma||Disease|| || || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,388: Line 1,546:  
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,393: Line 1,552:  
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,401: Line 1,561:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,413: Line 1,574:  
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
 
| ||
 
| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
 
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
 
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
 
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,436: Line 1,601:  
|
 
|
 
|HD
 
|HD
 +
|
 
|
 
|
 
|
 
|
Line 1,449: Line 1,615:  
|
 
|
 
|SK
 
|SK
 +
|
 
|
 
|
 
|
 
|
Line 1,455: Line 1,622:  
|-
 
|-
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
 
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
 
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
 
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
 
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
 
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
 
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
 
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
 
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
 
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
 
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
 
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
 
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
 
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
 
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
 +
|
 
|
 
|
 
|
 
|
Line 1,591: Line 1,791:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,609: Line 1,810:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,622: Line 1,824:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,635: Line 1,838:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,648: Line 1,852:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,661: Line 1,866:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,674: Line 1,880:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,687: Line 1,894:  
|
 
|
 
|GC
 
|GC
 +
|
 
|
 
|
 
|
 
|
Line 1,697: Line 1,905:  
|
 
|
 
----<br />
 
----<br />
 +
|
 
|
 
|
 
|
 
|
Line 1,708: Line 1,917:  
|-
 
|-
 
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
 
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Bloom syndrome||Disease|| || || || || ||NA|| ||
 
|Bloom syndrome||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
 
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
 
|-
 
|-
 
|RASopathies||Disease|| || || || || ||NA|| ||
 
|RASopathies||Disease|| || || || || ||NA|| ||
 +
|
 
|
 
|
 
|
 
|
 
|}
 
|}
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/13901"